TG Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on June 16, 2017, covering events occurring on June 14, 15, and 16, 2017. The company is a Delaware corporation focused on developing novel therapeutics for cancer and autoimmune diseases.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report is limited to the disclosure of specific corporate events.
Material Changes and Events
Under Item 8.01 (Other Events), the company announced the presentation of clinical study data at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. The data pertains to the following investigational therapies:
- TGR-1202 in combination with ibrutinib.
- TG-1101 in combination with TGR-1202 and bendamustine.
- TG-1101 plus ibrutinib (the GENUINE trial).
- TGR-1202 in combination with TG-1101 and ibrutinib.
Press releases detailing these results were issued on June 14, 15, and 16, 2017, and are incorporated as Exhibits 99.1, 99.2, and 99.3.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the reference to the clinical data presentations. Investors are directed to the attached press releases for details on the clinical results.
Key Facts for Investor Verification
- Verify the specific clinical data and efficacy results presented in the press releases filed as Exhibits 99.1, 99.2, and 99.3.
- Confirm the status of the GENUINE trial and other mentioned studies following the ICML presentation.
- Note that this 8-K contains no financial performance metrics; refer to the most recent 10-Q or 10-K for financial health.